Hansa Biopharma | Sustainability Performance
Hansa Biopharma AB specializes in developing enzyme-based therapeutics, focusing on treatments for rare immunological diseases and utilizing advanced biotechnology for product development.
2001
Sweden
51 - 200 employees
Biotechnology
$10M - 25M in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#1906
Overallⓘ#129
in Swedenⓘ#26
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Digital emissionsEnergy consumptionGovernance
Targets
Leading
Controversy level
- Hansa Biopharma's executive compensation was debated relative to its pre-profitability status.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
2-3
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.